EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel Rexinoid Agonist, UAB116, Decreases Metastatic Phenotype in Hepatoblastoma by Inhibiting the Wnt/β-Catenin Pathway via Upregulation of TRIM29

Swatika Butey iD, Morgan L Brown iD, Janet R Julson iD, Raoud Marayati iD, Venkatram R Atigadda iD, Maryam G Shaikh, Nazia Nazam, Colin H Quinn iD, Sorina Shirley, Laura L Stafman iD, Elizabeth A Beierle iD

International Journal of Molecular Sciences · 22.04.2025 · 26 (9) · 3933

DOI: 10.3390/ijms26093933 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.04.2025. Verfasst von Swatika Butey und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA. Hauptthemen laut MEDLINE: Hepatoblastoma, Wnt Signaling Pathway, Liver Neoplasms, Transcription Factors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCI/NIH, UAB Genomics Core.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatoblastoma (HB) is the most common pediatric primary liver tumor. About 20% of affected children have pulmonary metastasis at presentation. Survival rates for these children are dismal, not exceeding 25%. To study this subset of patients, we sequenced a metastatic HB cell line, HLM_2, and identified downregulation of the Liver X Receptor (LXR)/Retinoid X Receptor (RXR) pathway. LXR/RXRs function as transcriptional regulators that influence genes implicated in HB development, including the Wnt/β-catenin signaling pathway. We assessed the effects of a novel LXR/RXR agonist, UAB116, on metastatic HB, hypothesizing that this compound would affect genes governing the Wnt/β-catenin pathway, decreasing the metastatic phenotype of HLM_2 metastatic HB cells. We evaluated its effects on viability, proliferation, stemness, clonogenicity, and motility, and performed RNA sequencing to study differential gene regulation. Treatment with UAB116 for 72 h decreased HLM_2 proliferation, stemness, clonogenicity, and invasion. RNA sequencing identified an eight-fold increase in TRIM29, a gene known to inhibit β-catenin, in cells treated with UAB116. Administration of the LXR/RXR agonist, UAB116, reduces proliferation, stemness, and invasiveness of metastatic HB cells, potentially by upregulation of TRIM29, a known modulator of the Wnt/β-catenin pathway, providing support for further exploration of LXR/RXR agonism as a therapeutic strategy for metastatic HB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HepatoblastomaWnt Signaling PathwayLiver NeoplasmsTranscription FactorsDNA-Binding ProteinsHumansCell Line, TumorGene Expression Regulation, NeoplasticCell ProliferationLiver X ReceptorsUp-Regulationbeta CateninNeoplasm MetastasisPhenotypeCell Movement

Stichwörter der Autor:innen

Wnt/β-cateninhepatoblastomaliver X receptor (LXR)retinoid X receptor (RXR)tripartite motif containing 29 (TRIM 29)

Substanzen

Transcription FactorsDNA-Binding ProteinsLiver X Receptorsbeta Catenin

Autor:innen und Institutionen

  • Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
  • Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.

ORCID-Profile: Swatika Butey, Morgan L Brown, Janet R Julson, Raoud Marayati, Venkatram R Atigadda, Colin H Quinn, Laura L Stafman, Elizabeth A Beierle

Förderung

  • NCI NIH HHS
  • NCI/NIH
  • UAB Genomics Core
  • UAB Comprehensive Flow Cytometry Core
  • Kaul Pediatric Research Foundation
  • Destiny StrongER Foundation
  • Kaul Pediatric Research Foundation and Destiny StrongER

Zitieren

APA

Butey, S., Brown, M. L., Julson, J. R., Marayati, R., Atigadda, V. R., Shaikh, M. G., Nazam, N., Quinn, C. H., Shirley, S., Stafman, L. L., & Beierle, E. A. (2025). A Novel Rexinoid Agonist, UAB116, Decreases Metastatic Phenotype in Hepatoblastoma by Inhibiting the Wnt/β-Catenin Pathway via Upregulation of TRIM29. International Journal of Molecular Sciences, 26(9), 3933. https://doi.org/10.3390/ijms26093933

Vancouver

Butey S, Brown ML, Julson JR, Marayati R, Atigadda VR, Shaikh MG, et al. A Novel Rexinoid Agonist, UAB116, Decreases Metastatic Phenotype in Hepatoblastoma by Inhibiting the Wnt/β-Catenin Pathway via Upregulation of TRIM29. International Journal of Molecular Sciences. 2025;26(9):3933. doi:10.3390/ijms26093933

BibTeX
@article{Butey2025,
  author = {Butey, Swatika and Brown, Morgan L and Julson, Janet R and Marayati, Raoud and Atigadda, Venkatram R and Shaikh, Maryam G and Nazam, Nazia and Quinn, Colin H and Shirley, Sorina and Stafman, Laura L and Beierle, Elizabeth A},
  title = {A Novel Rexinoid Agonist, UAB116, Decreases Metastatic Phenotype in Hepatoblastoma by Inhibiting the Wnt/β-Catenin Pathway via Upregulation of TRIM29},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {9},
  pages = {3933},
  doi = {10.3390/ijms26093933}
}
Kostenlos starten →